Callisto Announces Sponsored Laboratory Study Agreement With M. D. Anderson Cancer Center on Degrasyn Anticancer Agents.
PR Newswire Europe, June, 2006
NEW YORK, June 15 /PRNewswire/ --
- Research Agreement to Support Biological Studies on New Tumor-Fighting Class of Drugs
Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced today that a sponsored laboratory study agreement has been executed with The University of Texas M. D. Anderson Cancer Center to support development of the Company's Degrasyn class of cancer-fighting compounds.
The two-year agreement is intended to support in-vitro and animal model studies to be performed by a group of research scientists at M. D. Anderson, who will focus on evaluating Degrasyn analogs being synthesized under the auspices of a separate executed...
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- Design a commission plan that drives sales - Sales Commissions
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
- LIFO vs. FIFO: a return to the basics
